X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
https://www.prnewswire.com/news-releases/oral-report--the-positive-interim-analysis-results-from-the-phase-iii-clinical-study-of-akesos--cadonilimab-pd-1ctla-4-bsab-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-cancer-presented-at-2024-aacr-302110917.html
https://www.globenewswire.com//news-release/2023/12/19/2798574/0/en/Processa-Pharmaceuticals-Provides-Interim-Analysis-from-Ongoing-Phase-1b-Trial-of-Next-Generation-Capecitabine-Showing-Improved-Safety-Over-Capecitabine.html
https://www.fiercebiotech.com/biotech/akeso-claims-overall-survival-win-its-bispecific-patients-severe-gastric-cancer
https://www.onclive.com/view/trifluridine-tipiracil-plus-bevacizumab-provides-potential-first-line-alternative-to-bevacizumab-capecitabine-in-mcrc
https://www.onclive.com/view/adjuvant-ibandronate-plus-capecitabine-does-not-significantly-improve-os-in-elderly-patients-with-early-breast-cancer
https://endpts.com/fusion-and-cyteir-refocus-pipelines-nona-biosciences-collaborating-with-pharmaessentia/
https://www.prnewswire.com/news-releases/carsgens-cldn18-2-mab-ab011-achieves-ind-clearance-from-the-nmpa-for-the-first-line-combination-treatment-of-gastric-cancer-301816842.html
https://endpts.com/project-renewal-fda-updates-older-genentech-cancer-drug-label/
https://www.clinicaltrialsarena.com/news/fda-aston-sci-cancer-vaccine/
https://www.clinicaltrialsarena.com/news/cg-pancreatic-adenocarcinoma-trial/
https://endpts.com/enhertu-strikes-again-with-a-phiii-success-in-another-breast-cancer-population/
http://www.pharmafile.com/news/608613/nice-draft-guidance-recommends-tucatinib-advanced-breast-cancer
https://www.biospace.com/article/releases/tempus-introduces-a-new-predictive-diagnostic-test-to-its-growing-collection-of-algorithms/?s=71
https://www.europeanpharmaceuticalreview.com/news/164614/nice-does-not-recommend-tucatinib-in-new-draft-guidance/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204345
https://www.esmo.org/oncology-news/elderly-patients-with-stage-iii-colon-cancer-may-derive-less-benefit-from-adjuvant-oxaliplatin-and-flouropyrimidines
https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine
https://www.fiercebiotech.com/biotech/seattle-genetics-breast-cancer-drug-hits-mark-pivotal-trial
https://www.prnewswire.com/news-releases/armas-pharmaceuticals-expands-generic-portfolio-with-launches-of-capecitabine-and-imatinib-300825348.html
https://www.businesswire.com/news/home/20181217005783/en/Puma-Biotechnology-Announces-Top-Line-Results-Phase/
https://www.ema.europa.eu/documents/product-information/capecitabine-accord-epar-product-information_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209365
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-16-2018-1526446624.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210604
https://endpts.com/restless-seattle-genetics-snaps-up-a-pivotal-stage-cancer-drug-with-614m-cascadian-buyout-pact/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208820
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207652
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204741
https://www.europeanpharmaceuticalreview.com/48558/news/industry-news/astrazeneca-phase-iii-breast-cancer/
http://www.fiercepharma.com/pharma-asia/aslan-poses-positive-top-line-varlitinib-phase-2-data-breast-cancer
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207456
http://www.pmlive.com/pharma_news/pfizers_first-in-class_breast_cancer_therapy_wins_eu_licensing_1176260?
http://www.europeanpharmaceuticalreview.com/45177/news/industry-news/eribulin-breast-cancer/?
https://www.pharmacompass.com/pdf/news/approved-new-list-of-candidate-drugs-to-bioisencao-1475582007.pdf
https://www.pharmacompass.com/pdf/news/zhejiang-hisun-pharmaceutical-co-ltd-yantou-campus-fails-edqm-inspection-1483966941.pdf
http://www.pharma-excipients.ch/2016/09/18/formulation-and-development-of-colon-specific-multiparticulate-system-of-capecitabine/
http://www.pharmatimes.com/Article/16-03-18/Welsh_gov_overrules_NICE_rejection_of_Celgene_s_pancreatic_cancer_drug.aspx
http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0732-2016&w=03092016&lang=eng
http://www.business-standard.com/article/companies/dr-reddy-s-plans-to-pursue-inorganic-opportunities-116021700328_1.html
http://aux.cphi-online.com/incyte-decides-to-discontinue-janus-studies-of-news039099.html
Market Place
Share 
